Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Contineum Therapeutics Inc CTNM

Healthcare Biotechnology
Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation, and immunology (NI&I) indications with high unmet need. Its pipeline includes PIPE-791, CTX-343, and... see more

Recent & Breaking News (NDAQ:CTNM)

    Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)

    Business Wire 6 days ago

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    GlobeNewswire 8 days ago

    Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

    Business Wire December 16, 2024

    Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference

    Business Wire November 25, 2024

    Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain

    Business Wire November 18, 2024

    Contineum Therapeutics to Attend Upcoming Investor Conferences

    Business Wire November 13, 2024

    Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    Business Wire November 6, 2024

    Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences

    Business Wire August 28, 2024

    Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

    Business Wire August 13, 2024

    Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis

    Business Wire July 31, 2024

    Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Business Wire June 24, 2024

    Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference

    Business Wire June 4, 2024

    Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary

    Business Wire June 3, 2024

    Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors

    Business Wire May 20, 2024

    Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

    Business Wire May 16, 2024